The Asia Pacific Lupus Collaboration (APLC) is a collaboration of expert lupus clinicians and researchers from 24 centres across Australia, China, Hong Kong, Indonesia, Japan, Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand and United Arab Emirates (Figure 1). It was formed in 2012 to improve outcomes for patients with systemic lupus erythematosus (SLE).
SLE, or lupus, is an autoimmune disease that causes the body's immune system to attack vital organs. There is no single effective targeted therapy for SLE. This means that, along with suffering symptoms of the disease, patients also suffer severe toxicity from the use of corticosteroids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and are at risk of permanent organ damage over time.
The Asia Pacific region has a high frequency of SLE with high disease activity, which allows this region special advantage in research aimed at defining clinical endpoints. The APLC is taking this opportunity for collaborative research, and making contributions to knowledge on the disease and its treatment, on a global scale. Find out about our research and meet our members.
APLC sites (Figure 1)